Home > Publications Database > OCT-Based Differentiation of First Acute Optic Neuritis: An International Study of 111 Patients With NMOSD and MOGAD. > print

001     283151
005     20260128104031.0
024 7 _ |a 10.1212/NXI.0000000000200531
|2 doi
024 7 _ |a pmid:41499724
|2 pmid
037 _ _ |a DZNE-2026-00047
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Pakeerathan, Thivya
|0 0009-0000-4271-4763
|b 0
245 _ _ |a OCT-Based Differentiation of First Acute Optic Neuritis: An International Study of 111 Patients With NMOSD and MOGAD.
260 _ _ |a Philadelphia, Pa.
|c 2026
|b Wolters Kluwer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1769591547_29847
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Severe optic neuritis (ON) is a common clinical manifestation in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD). Given distinct prognoses and often the necessity of early plasma exchange in NMOSD, prompt differentiation is crucial. In this study, we investigated the utility of optical coherence tomography (OCT) in differentiating between first acute NMOSD-ON and MOGAD-associated optic neuritis (MOGAD-ON), as well as specific factors associated with disc edema.In this retrospective multicenter study, 111 adult patients with MOGAD or aquaporin-4 antibody-positive NMOSD who experienced a first ON and underwent OCT within 2 weeks of symptom onset were included from 14 centers across 8 countries. Peripapillary retinal nerve fiber layer (pRNFL) thickness in µm was analyzed, including the average of both eyes in cases of bilateral manifestation.Eighty-three patients with MOGAD (51 women; 124 ON eyes; bilateral ON 48.2%) and 28 with NMOSD (24 women; 36 ON eyes; bilateral ON 21.4%) were enrolled. A significant increase in pRNFL thickness (>2SD), suggestive of disc edema, was observed in 73.4% of MOGAD-ON eyes and 11.1% of NMOSD-ON eyes (p < 0.001). The pRNFL thickness cutoff of 117.5 µm provided 92.9% specificity and 71.1% sensitivity in distinguishing between MOGAD-ON and NMOSD-ON (area under the curve = 0.838). There was no association between pRNFL thickening and MOG-IgG titer (high vs low), body mass index, or the delay between ON onset and OCT. Simultaneous bilateral MOGAD-ON was associated with significantly more pronounced pRNFL thickening.Acute-stage OCT contributes to the rapid and accurate differentiation between MOGAD-ON and NMOSD-ON prior to antibody confirmation, which can be critical for timely therapeutic decisions.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Myelin-Oligodendrocyte Glycoprotein
|2 NLM Chemicals
650 _ 7 |a Aquaporin 4
|2 NLM Chemicals
650 _ 7 |a Autoantibodies
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Tomography, Optical Coherence: methods
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Optic Neuritis: diagnostic imaging
|2 MeSH
650 _ 2 |a Optic Neuritis: diagnosis
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Neuromyelitis Optica: diagnosis
|2 MeSH
650 _ 2 |a Neuromyelitis Optica: diagnostic imaging
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Diagnosis, Differential
|2 MeSH
650 _ 2 |a Myelin-Oligodendrocyte Glycoprotein: immunology
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
650 _ 2 |a Aquaporin 4: immunology
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Autoantibodies
|2 MeSH
650 _ 2 |a Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
|2 MeSH
700 1 _ |a Davis, James
|0 0009-0001-2618-4894
|b 1
700 1 _ |a Henderson, Amanda D
|0 0000-0002-8676-4292
|b 2
700 1 _ |a Sotirchos, Elias S
|0 0000-0002-8812-1637
|b 3
700 1 _ |a Said, Yana
|0 0009-0004-4350-1910
|b 4
700 1 _ |a Havla, Joachim
|0 0000-0002-4386-1340
|b 5
700 1 _ |a Ringelstein, Marius
|0 0000-0003-3618-8407
|b 6
700 1 _ |a Aktas, Orhan
|0 0000-0002-2020-9210
|b 7
700 1 _ |a Weise, Margit
|b 8
700 1 _ |a Gernert, Jonathan A
|0 0000-0002-6655-5557
|b 9
700 1 _ |a Kornek, Barbara
|0 0000-0002-1851-6967
|b 10
700 1 _ |a Bsteh, Gabriel
|0 0000-0002-0825-0851
|b 11
700 1 _ |a Rommer, Paulus S
|0 0000-0001-5209-6647
|b 12
700 1 _ |a Krajnc, Nik
|0 0000-0002-4146-5870
|b 13
700 1 _ |a Pröbstel, Anne-Katrin
|0 P:(DE-2719)9003515
|b 14
700 1 _ |a Papadopoulou, Athina
|0 0000-0002-0367-1008
|b 15
700 1 _ |a Kulsvehagen, Laila
|0 0000-0001-5236-8323
|b 16
700 1 _ |a Pretzsch, Roxanne
|0 0009-0001-4129-1276
|b 17
700 1 _ |a Schoenholzer, Kean
|0 0009-0004-7755-4447
|b 18
700 1 _ |a Padungkiatsagul, Tanyatuth
|0 0000-0002-5840-6172
|b 19
700 1 _ |a Moss, Heather E
|0 0000-0003-4373-447X
|b 20
700 1 _ |a Villarreal Navarro, Sylvia E
|0 0009-0002-1013-7417
|b 21
700 1 _ |a Herwerth, Marina
|0 0000-0001-5125-4594
|b 22
700 1 _ |a Graure, Madalina
|0 0009-0003-5249-4567
|b 23
700 1 _ |a Kana, Veronika
|0 0000-0002-9362-3156
|b 24
700 1 _ |a Stiebel-Kalish, Hadas
|0 0000-0001-7715-6706
|b 25
700 1 _ |a Zlatkin, Rita
|b 26
700 1 _ |a Arnold, Anthony C
|0 0000-0002-9015-4542
|b 27
700 1 _ |a Bonelli, Laura
|0 0000-0001-8819-3756
|b 28
700 1 _ |a Stellmann, Jan-Patrick
|0 0000-0003-2565-2833
|b 29
700 1 _ |a Stolowy, Natacha
|0 0000-0003-3662-3800
|b 30
700 1 _ |a Schwake, Carolin
|0 0000-0003-3669-7244
|b 31
700 1 _ |a Schneider-Gold, Christiane
|0 0000-0002-9232-201X
|b 32
700 1 _ |a Kümpfel, Tania
|0 0000-0001-7509-5268
|b 33
700 1 _ |a Albrecht, Philipp
|0 0000-0001-7987-658X
|b 34
700 1 _ |a Rattanathamsakul, Natthapon
|0 0000-0002-1698-0520
|b 35
700 1 _ |a Pittock, Sean J
|0 0000-0002-6140-5584
|b 36
700 1 _ |a Flanagan, Eoin P
|0 0000-0002-6661-2910
|b 37
700 1 _ |a Carta, Sara
|0 0000-0001-5248-456X
|b 38
700 1 _ |a Mariotto, Sara
|0 0000-0002-7806-3103
|b 39
700 1 _ |a Gold, Ralf
|0 0000-0002-7223-3052
|b 40
700 1 _ |a Chen, John J
|0 0000-0003-3644-7528
|b 41
700 1 _ |a Ayzenberg, Ilya
|0 0009-0007-9491-2180
|b 42
773 _ _ |a 10.1212/NXI.0000000000200531
|g Vol. 13, no. 2, p. e200531
|0 PERI:(DE-600)2767740-0
|n 2
|p e200531
|t Neurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology
|v 13
|y 2026
|x 2332-7812
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/283151/files/DZNE-2026-00047.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/283151/files/DZNE-2026-00047.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:283151
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)9003515
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2026
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-27
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROL-NEUROIMMUNOL : 2022
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-13T18:57:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-13T18:57:06Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-27
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2021-02-13T18:57:06Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-27
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROL-NEUROIMMUNOL : 2022
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-27
920 1 _ |0 I:(DE-2719)1013045
|k AG Pröbstel
|l Clinical Neurology and Neuroimmunology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1013045
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21